title: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
abstract: Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.
authors.affiliation: Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA. Judith.steenbergen@cubist.com
authors.forename: Judith N
authors.initials: JN
authors.lastname: Steenbergen
authors.forename: Jeff
authors.initials: J
authors.lastname: Alder
authors.forename: Grace M
authors.initials: GM
authors.lastname: Thorne
authors.forename: Francis P
authors.initials: FP
authors.lastname: Tally
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D017576:Daptomycin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin